In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates

In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates

ABSTRACT: Objectives: A novel ß-lactam-β-lactamase inhibitor (BLBI), meropenem (MEM), combined with the boronate-based inhibitor vaborbactam (VAB), has recently been introduced for the treatment of infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales. The purpos...

Full description

Bibliographic Details
Main Authors: Jacqueline Findlay, Laurent Poirel, Patrice Nordmann
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Journal of Global Antimicrobial Resistance
Subjects:
Klebsiella pneumoniae
Meropenem-vaborbactam
KPC
Carbapenemase
Antibiotic resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S2213716523000012

Internet

http://www.sciencedirect.com/science/article/pii/S2213716523000012

Similar Items